Respiratory Medicine
Volume 104, Issue 3 , Pages 448-453 , March 2010

Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak

  • Seung Heon Lee

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
    • ,
  • Woo Jin Lew

      Affiliations

    • Korean Institute of Tuberculosis, Seoul, South Korea
    • ,
  • Hee Jin Kim

      Affiliations

    • Korean Institute of Tuberculosis, Seoul, South Korea
    • ,
  • Hyun-Kyung Lee

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
    • ,
  • Young Min Lee

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
    • ,
  • Chong Hee Cho

      Affiliations

    • Public Healthcare Center, Seoul, South Korea
    • ,
  • Eun Joo Lee

      Affiliations

    • Public Healthcare Center, Seoul, South Korea
    • ,
  • Dong Yeol Lee

      Affiliations

    • Public Healthcare Center, Seoul, South Korea
    • ,
  • Sung Weon Ryu

      Affiliations

    • Korean Institute of Tuberculosis, Seoul, South Korea
    • ,
  • Soo Yeon Oh

      Affiliations

    • Korean Institute of Tuberculosis, Seoul, South Korea
    • ,
  • Sin Ok Kim

      Affiliations

    • Korean Institute of Tuberculosis, Seoul, South Korea
    • ,
  • Tae Sun Shim

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 138-736, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 3010 3892; fax: +82 2 3010 6968.

Received 22 July 2009 ,Accepted 8 October 2009.

References 

  1. WHO report 2008 . global tuberculosis control, surveillance, planning, financing. Geneva, Switzerland: World Health Organization; 2008;
  2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–1021
  3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA. 1999;282:677–686
  4. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002;19:765–775
  5. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002;347:1860–1866
  6. American Thoracic Society/Centers for Disease Control and Prevention . Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221–S247
  7. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–354
  8. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–184
  9. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356:1099–1104
  10. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med. 2005;11:195–202
  11. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49–55
  12. National Institute for Health and Clinical Excellence . Clinical guideline 33. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. <www.nice.org.uk/CG033>2006;
  13. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J. 2006;28:35–44
  14. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J. 2006;28:45–50
  15. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006;174:831–839
  16. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006;174:349–355
  17. Wilkinson KA, Kon OM, Newton SM, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006;193:354–359
  18. Hill PC, Brookes RH, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007;4:e192
  19. Franken WP, Arend SM, Thijsen SF, et al. Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts. Int J Tuberc Lung Dis. 2008;12:1286–1294
  20. Hill PC, Jeffries DJ, Brookes RH, et al. Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS ONE. 2007;2:e183
  21. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49–58
  22. Updated recommendations on interferon gamma release assays for latent tuberculosis infection . An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2008;34:1–13
  23. National Tuberculosis Advisory Committe . Position statement on interferon-gamma release immunoassays in the detection of latent tuberculosis infection, October 2007. Commun Dis Intell. 2007;31:404–405
  24. Guidelines for the investigation of contacts of persons with infectious tuberculosis . Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54:1–47
  25. Diel R, Forssbohm M, Loytved G, et al. [Recommendations for background studies in tuberculosis], Pneumologie. 2007;61:440–455
  26. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med. 2007;175:282–287
  27. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology. 2008;13:468–472
  28. Lew WJ, Jung YJ, Song JW, et al. Combined use of QuantiFERON((R))-TB Gold assay and chest computed tomography in a tuberculosis outbreak. Int J Tuberc Lung Dis. 2009;13:633–639
  29. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res. 2006;7:77
  30. Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis. 2005;9:1242–1247
  31. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med. 2007;175:618–627
  32. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis. 2009;13:84–92
  33. Bosshard V, Roux-Lombard P, Perneger T, et al. Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis?. Respir Med. 2009;103:30–34
  34. Dheda K, Pooran A, Pai M, et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J Infect. 2007;55:169–173
  35. Pai M, Joshi R, Dogra S, et al. Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol. 2006;1:7
  36. Higuchi K, Okada K, Harada N, Mori T. [Effects of prophylaxis on QuantiFERON TB-2G responses among children], Kekkaku. 2008;83:603–609
  37. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2004;170:832–835
  38. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 1989;140:1189–1193

PII: S0954-6111(09)00327-8

doi: 10.1016/j.rmed.2009.10.006

Respiratory Medicine
Volume 104, Issue 3 , Pages 448-453 , March 2010

Article Tools

* Image Usage & Resolution